Rupal A Patel

发表

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.

T. Hermann, C. Kissinger, Qiang Zhao, 2008, Bioorganic & medicinal chemistry letters.

5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

Matthew A. Lardy, C. Kissinger, Qiang Zhao, 2009, Bioorganic & medicinal chemistry letters.

Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients

C. Belluco, M. Lise, Rupal A Patel, 2000 .

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A. Drilon, M. Ahn, A. Wozniak, 2018, Cancer discovery.

Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum.

M. O'Neil-Johnson, Rupal A Patel, B. Li, 2007, Journal of natural products.

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.

P. A. Thompson, J. Khandurina, C. Kissinger, 2009, Bioorganic & medicinal chemistry letters.

Identification of ligand binding by protein stabilization: comparison of ATLAS with biophysical and enzymatic methods.

P. A. Thompson, R. Showalter, Rupal A Patel, 2008, Assay and drug development technologies.

Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.

Jingjing Zhao, Matthew A. Lardy, Frank Ruebsam, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.

C. Kissinger, Qing Han, Michael Noble, 2008, Bioorganic & medicinal chemistry letters.

5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

Yuefen Zhou, S. Webber, D. Murphy, 2009, Bioorganic & medicinal chemistry letters.

A diketopiperazine dimer from a marine-derived isolate of Aspergillus niger.

Rupal A Patel, K. Steffy, Natalie N. M. Nguyen, 2004, Journal of natural products.

In Vitro Combination of ANA598 with Other Anti-HCV Agents can Eliminate the Emergence of Resistant Colonies

P. A. Thompson, R. Showalter, Rupal A Patel, 2010 .

In Vitro Combination Studies of ANA598 with Anti-HCV Agents Demonstrate Enhanced Anti-viral Activity

P. A. Thompson, R. Showalter, Rupal A Patel, 2010 .

673 ENHANCED IN VITRO ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH OTHER ANTI-HCV AGENTS SUPPORT COMBINATION TREATMENT

P. A. Thompson, R. Showalter, Rupal A Patel, 2010 .

90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT

P. A. Thompson, Rupal A Patel, K. Steffy, 2009 .

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

A. Drilon, A. Shaw, S. Ou, 2016 .

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

M. Ladanyi, A. Drilon, Shunqi Yan, 2016, Clinical Cancer Research.

Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.

C. Kissinger, Qiang Zhao, Yuefen Zhou, 2008, Bioorganic & medicinal chemistry letters.

4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.

Matthew A. Lardy, C. Kissinger, Qing Han, 2008, Bioorganic & medicinal chemistry letters.

ATLAS--a high-throughput affinity-based screening technology for soluble proteins: technology application using p38 MAP kinase.

P. A. Thompson, Rupal A Patel, L. LeBrun, 2008, Assay and drug development technologies.

A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.

A. Drilon, M. Fakih, L. Bazhenova, 2016 .

Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

M. Fakih, A. Lockhart, Rupal A Patel, 2015 .

Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.

Qiang Zhao, Helen McGuire, Alberto Gobbi, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.

C. Kissinger, Qiang Zhao, Yuefen Zhou, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.

Matthew A. Lardy, Yuefen Zhou, S. Webber, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.

T. Hermann, C. Kissinger, Qiang Zhao, 2008, Bioorganic & medicinal chemistry letters.

5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

Matthew A. Lardy, C. Kissinger, Qiang Zhao, 2009, Bioorganic & medicinal chemistry letters.